Ginkgo Bioworks (DNA) News Today $10.82 +0.62 (+6.03%) As of 01/17/2025 03:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Ginkgo Bioworks (NYSE:DNA) Shares Gap Up - Here's What HappenedGinkgo Bioworks (NYSE:DNA) Shares Gap Up - What's Next?January 17, 2025 | marketbeat.comGinkgo Bioworks (NYSE:DNA) Trading 9.1% Higher - Still a Buy?Ginkgo Bioworks (NYSE:DNA) Trading Up 9.1% - Still a Buy?January 16, 2025 | marketbeat.comGinkgo Bioworks (NYSE:DNA) Shares Gap Up - Should You Buy?Ginkgo Bioworks (NYSE:DNA) Shares Gap Up - Here's WhyJanuary 15, 2025 | marketbeat.comTD Cowen Remains a Buy on Ginkgo Bioworks Holdings (DNA)January 15, 2025 | markets.businessinsider.comGinkgo Bioworks, Universal Cells form research collaborationJanuary 14, 2025 | markets.businessinsider.comGinkgo Bioworks Partners with Universal Cells, an Astellas Company, to Advance Next-Generation iPSC-Derived Cell Therapies for Solid TumorsJanuary 13, 2025 | prnewswire.comRegeneron Collaborates with Truveta and Leading American Health Systems to Massively Extend its DNA Sequence-Linked Healthcare Database to Further Advance Scientific Innovation and Healthcare DeliveryJanuary 13, 2025 | globenewswire.comGinkgo Bioworks (NYSE:DNA) Trading Down 9.1% - What's Next?Ginkgo Bioworks (NYSE:DNA) Shares Down 9.1% - What's Next?January 10, 2025 | marketbeat.comRapid Rise of Synthetic Biology Fuels Enzymatic DNA Synthesis Boom Across Biopharma and GenomicsJanuary 9, 2025 | globenewswire.comGinkgo Bioworks Announces Participation in the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 9, 2025 | prnewswire.comBarclays PLC Has $98,000 Stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)Barclays PLC trimmed its position in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 91.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 11,942 shares of the company's stock after selJanuary 9, 2025 | marketbeat.comGinkgo Bioworks (NYSE:DNA) Trading 6.5% Higher - Here's WhyGinkgo Bioworks (NYSE:DNA) Trading Up 6.5% - Time to Buy?January 7, 2025 | marketbeat.comGinkgo Bioworks Holdings, Inc. (NYSE:DNA) Shares Sold by Geode Capital Management LLCGeode Capital Management LLC reduced its holdings in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 97.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 416,631 shares of the compJanuary 7, 2025 | marketbeat.comGinkgo Bioworks Holdings, Inc. (NYSE:DNA) Shares Sold by State Street CorpState Street Corp cut its stake in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 97.9% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 216,021 shares of the company's stock after selling 9,876,644 shares during the pJanuary 2, 2025 | marketbeat.comGinkgo Bioworks (NYSE:DNA) Trading Up 6.4% - Time to Buy?Ginkgo Bioworks (NYSE:DNA) Stock Price Up 6.4% - Still a Buy?December 31, 2024 | marketbeat.comGinkgo Bioworks (NYSE:DNA) Shares Down 7.9% - Time to Sell?Ginkgo Bioworks (NYSE:DNA) Trading Down 7.9% - What's Next?December 30, 2024 | marketbeat.comGinkgo Bioworks (NYSE:DNA) Shares Gap Down - Here's WhyGinkgo Bioworks (NYSE:DNA) Shares Gap Down - Should You Sell?December 26, 2024 | marketbeat.comGinkgo Bioworks falls -7.7%December 24, 2024 | markets.businessinsider.comGinkgo Bioworks (NYSE:DNA) Shares Down 6.6% - Here's What HappenedGinkgo Bioworks (NYSE:DNA) Shares Down 6.6% - Time to Sell?December 23, 2024 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 1,865,335 Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 98.1% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutionaDecember 22, 2024 | marketbeat.comGinkgo Bioworks (NYSE:DNA) Stock Price Up 4.1% - Time to Buy?Ginkgo Bioworks (NYSE:DNA) Stock Price Up 4.1% - What's Next?December 20, 2024 | marketbeat.comTeachers Retirement System of The State of Kentucky Sells 836,539 Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)Teachers Retirement System of The State of Kentucky cut its position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 97.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,448 shareDecember 20, 2024 | marketbeat.comGinkgo Bioworks eligible for $9.4M in partnership for bioelectronic devicesDecember 18, 2024 | markets.businessinsider.comGinkgo Bioworks, Carnegie Mellon University Secure $9.4 Mln To Build Devices For Disease TreatmentDecember 17, 2024 | markets.businessinsider.comGinkgo Bioworks Awarded $9.4 Million in Partnership with Carnegie Mellon University to Develop Implantable Cell-Based Bioelectronic Devices for Disease Treatment Under ARPA-H's REACT ProgramDecember 17, 2024 | prnewswire.comCharles Schwab Investment Management Inc. Decreases Position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)Charles Schwab Investment Management Inc. lowered its stake in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 96.8% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 216,345 shares of the company's stock after selling 6,469December 17, 2024 | marketbeat.comJanus Henderson Group PLC Decreases Stock Holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)Janus Henderson Group PLC lessened its holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 97.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 14,533 shares of the company's stock after selling 56December 16, 2024 | marketbeat.comGinkgo Bioworks (NYSE:DNA) Shares Down 5.5% - Here's WhyGinkgo Bioworks (NYSE:DNA) Stock Price Down 5.5% - Here's WhyDecember 13, 2024 | marketbeat.comVerition Fund Management LLC Makes New Investment in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)Verition Fund Management LLC purchased a new position in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 97,200 shares of the company's stock, valued at approximatDecember 10, 2024 | marketbeat.comGinkgo Bioworks Holdings, Inc. (NYSE:DNA) Holdings Trimmed by Zurcher Kantonalbank Zurich CantonalbankZurcher Kantonalbank Zurich Cantonalbank trimmed its position in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 97.5% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 3,700 shares of the company's stockDecember 10, 2024 | marketbeat.com157,862 Shares in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Purchased by BNP Paribas Financial MarketsBNP Paribas Financial Markets bought a new stake in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 157,862 shares of the company's stock, valued at approximatelyDecember 10, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Buys Shares of 279,954 Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)Jacobs Levy Equity Management Inc. bought a new stake in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 279,954 shares of the company'sDecember 8, 2024 | marketbeat.comErste Asset Management GmbH Purchases Shares of 500,000 Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)Erste Asset Management GmbH acquired a new position in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 500,000 shares of tDecember 3, 2024 | marketbeat.comPDT Partners LLC Makes New Investment in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)PDT Partners LLC bought a new stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 147,162 shares of the company's stock, valued at approximately $1,199,000. PDT PaDecember 2, 2024 | marketbeat.comAnchorage Capital Group L.L.C. Sells 68,158,230 Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)Anchorage Capital Group L.L.C. trimmed its stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 97.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,746,363 shares of the company's stock after sellNovember 29, 2024 | marketbeat.comGinkgo Bioworks Holdings, Inc. (NYSE:DNA) Stock Holdings Cut by AH Capital Management L.L.C.AH Capital Management L.L.C. reduced its position in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 97.5% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 108,568 shares of the company's stock after seNovember 27, 2024 | marketbeat.comGinkgo Bioworks Holdings, Inc. (NYSE:DNA) Shares Sold by Tao Capital Management LPTao Capital Management LP trimmed its position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 97.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,683 shares of the company's stock after selling 221,671November 20, 2024 | marketbeat.comGinkgo Bioworks Holdings: Hold Rating Amidst Revenue Growth and Restructuring EffortsNovember 19, 2024 | markets.businessinsider.comUS Bancorp DE Decreases Stock Holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)US Bancorp DE decreased its position in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 97.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,336 shares of the company's stock aftNovember 19, 2024 | marketbeat.comGinkgo Bioworks: Unproven Transition But 2025 Is Looking BetterNovember 18, 2024 | seekingalpha.comGinkgo Bioworks Holdings, Inc. (NYSE:DNA) Sees Significant Drop in Short InterestGinkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report) saw a large decline in short interest in the month of October. As of October 31st, there was short interest totalling 7,330,000 shares, a decline of 7.0% from the October 15th total of 7,880,000 shares. Currently, 20.7% of the company's shares are sold short. Based on an average daily trading volume, of 1,360,000 shares, the short-interest ratio is currently 5.4 days.November 18, 2024 | marketbeat.comGinkgo Bioworks Holdings, Inc. (NYSE:DNA) Shares Sold by GSA Capital Partners LLPGSA Capital Partners LLP lessened its holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 95.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 120,169 shares of the company's stock after sNovember 16, 2024 | marketbeat.comGinkgo Bioworks price target lowered to $6 from $7 at BTIGNovember 15, 2024 | markets.businessinsider.comPositive Outlook for Ginkgo Bioworks: Strategic Developments and Financial Strength Bolster Buy RatingNovember 14, 2024 | markets.businessinsider.comGinkgo Bioworks Reports Q3 Growth and Strategic DealsNovember 14, 2024 | markets.businessinsider.comGinkgo Bioworks Holdings, Inc. (NYSE:DNA) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | msn.comGinkgo Bioworks: Not Enough ProgressNovember 13, 2024 | seekingalpha.comBaillie Gifford & Co. Trims Holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)Baillie Gifford & Co. lowered its stake in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 97.5% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 3,358,581 shares of the company's stock after selling 131,067,285 shares during the periodNovember 13, 2024 | marketbeat.comGinkgo Bioworks Holdings Inc (DNA) Q3 2024 Earnings Call Highlights: Strategic Restructuring ...November 13, 2024 | finance.yahoo.comGinkgo Bioworks Holdings, Inc. (DNA) Q3 2024 Earnings Call TranscriptNovember 12, 2024 | seekingalpha.com Get Ginkgo Bioworks News Delivered to You Automatically Sign up to receive the latest news and ratings for DNA and its competitors with MarketBeat's FREE daily newsletter. Email Address DNA Media Mentions By Week DNA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DNA News Sentiment▼0.440.46▲Average Medical News Sentiment DNA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DNA Articles This Week▼57▲DNA Articles Average Week Get Ginkgo Bioworks News Delivered to You Automatically Sign up to receive the latest news and ratings for DNA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Edgewise Therapeutics News Today HUTCHMED News Today Arrowhead Pharmaceuticals News Today Mirum Pharmaceuticals News Today Harmony Biosciences News Today CG Oncology News Today Protagonist Therapeutics News Today NewAmsterdam Pharma News Today Janux Therapeutics News Today Vera Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:DNA) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ginkgo Bioworks Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ginkgo Bioworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DNA Stock Alerts